Beyond skin deep: Claims, compliance and care in the aesthetics arena

The aesthetics sector has evolved from a niche market into a significant part of the wider health, wellbeing and lifestyle economy, bringing with it increased scrutiny of standards, governance and patient safety.

The scale of that expansion is striking. The British Beauty Council reports annual UK market growth of around 8-10%, while industry data suggests a 437% rise in practitioners and a 357% increase in Botox clinics between 2023 and 2025. Over the same period, the proportion of non-medical practitioners reportedly grew from around 12% to almost 25%.

Data published by the British College of Aesthetic Medicine (BCAM) recorded 1,913 complications managed by its members during 2024 and 3,547 corrective treatments undertaken following procedures performed by other practitioners. The BCAM further reported that approximately 60% of those cases requiring corrective treatment arose from procedures carried out by beauticians rather than healthcare professionals. Viewed in the context of a growing sector, these figures underline the importance of effective training, governance and patient safeguards. For practitioners, providers, insurers and indemnifiers, many of the issues that give rise to complaints, claims and regulatory scrutiny arise not from the technical delivery of treatment itself, but from the surrounding processes: consent, communication, patient safeguarding, record keeping, regulatory compliance and accountability.

Consent, communication and expectation management: the enduring claims battleground

While treatments, products and technologies continue to advance, the issues at the heart of many complaints and claims remain remarkably familiar Aesthetic outcomes are inherently subjective. Unlike many areas of healthcare, success is often measured not by clinical indicators but by patient perception. Treatment may be delivered competently and in accordance with accepted practice yet still give rise to dissatisfaction where expectations and outcomes do not align.

Managing those expectations remains one of the most effective risk-management tools available to practitioners. Informed consent requires considerably more than a signed document. Patients should understand the proposed treatment, its expected benefits, material risks, potential complications, alternative options and the limitations of what can realistically be achieved. In many disputes, the key question is not whether treatment was performed appropriately, but whether the patient was given sufficient information to make an informed decision.

Technology adds a further layer of complexity. AI-powered consultation tools, facial analysis software and treatment visualisations can support patient understanding, but they may also create unrealistic expectations if illustrations are perceived as predictions. Where outcomes differ from those visualisations, disputes may focus on what was explained during the consultation and whether expectations were properly managed.

Assessment of patient suitability extends beyond physical presentation and treatment goals. Body dysmorphic disorder and other vulnerabilities may affect both the appropriateness of treatment and a patient's expectations of outcome. Recognising potential vulnerabilities and understanding a patient's motivations for treatment are important aspects of safe and appropriate care. Particularly where a patient is new to treatment, allowing time for reflection between consultation and procedure can also help ensure decisions are considered rather than impulsive.

Ultimately, many complaints arise not because something has gone clinically wrong, but because expectations, understanding and outcomes have become misaligned. Effective communication, thorough consultations, realistic discussions regarding outcomes and robust documentation remain among the strongest safeguards available.

Data, AI and record keeping: governance remains critical

Technology is transforming almost every stage of the patient journey, from initial enquiries and bookings through to consultations, treatment planning and aftercare.

AI is increasingly used to support administration, patient communications, consultation notes and record creation. While these tools can deliver significant efficiencies, they do not alter a fundamental principle: responsibility for the content and accuracy of patient records remains with the practitioner.

That principle becomes particularly important when complaints or claims arise. Contemporaneous records often provide the most persuasive evidence of what information was provided, what risks and treatment options were discussed, what decisions were made and whether appropriate processes were followed. Consultation notes, consent documentation, photographs, treatment records and follow-up communications may all prove critical when events are scrutinised months or years later. Poor records can significantly undermine the defence of a claim; good records often provide some of the strongest protection available.

The use of AI-enabled and cloud-based systems also creates important data protection and governance considerations. Those responsible for handling patient data should understand how it is processed and stored, whether third-party providers are involved, and whether appropriate contractual, security and governance safeguards are in place.

Digital risk extends beyond clinical records. In a reputation-driven sector, online reviews and social media commentary can have significant commercial consequences. While not every adverse review can or should be challenged, legal and practical remedies may be available where content is inaccurate, discloses personal data, breaches platform terms or is posted by someone who was not a genuine patient. Depending on the circumstances, practitioners may be able to rely on platform reporting mechanisms, UK GDPR rights, including rectification or erasure rights, or, in more serious cases, defamation or malicious falsehood remedies. However, removal is rarely straightforward and outcomes will depend on the nature and accuracy of the content.

As with complaints more generally, prevention is preferable to cure. Effective communication, expectation management, robust record keeping and clear complaint-handling processes remain among the most effective means of reducing both legal and reputational risk.

Technology may change how records are created and maintained, but it does not change the standards of accuracy, completeness and accountability they are expected to meet.

Regulation: progress, but uncertainty remains

Questions surrounding regulation have accompanied the growth of the aesthetics sector for many years.

One of the defining features of the current landscape is that there is no dedicated regulator responsible for aesthetics as a standalone sector. Regulation generally follows the practitioner rather than the procedure. Doctors, nurses, dentists and pharmacists remain accountable to their existing professional regulators, while many non-healthcare practitioners operate outside equivalent statutory frameworks. This creates an uneven regulatory landscape in which similar procedures may be subject to very different levels of oversight.

In response, a range of voluntary registers, accreditation schemes and professional organisations, including the Joint Council for Cosmetic Practitioners (JCCP), Save Face, the BCAM and the British Association of Cosmetic Nurses (BACN), have sought to promote standards, education and good practice. While these initiatives have played an important role, participation remains voluntary and the wider regulatory framework remains fragmented.

The Health and Care Act 2022 signalled a potential shift in direction by creating powers for the introduction of a licensing scheme for certain cosmetic procedures in England, reflecting a clear policy intention to strengthen oversight and enhance patient protection.

However, the existence of enabling legislation should not be mistaken for a fully developed regulatory regime. Any licensing framework remains some way from becoming operational, with further consultation and secondary legislation still required. Important questions remain regarding its scope, the procedures that will be covered, eligibility criteria, enforcement and how the regime will operate in practice.

For practitioners, providers and insurers, the more immediate challenge is navigating a sector in which regulatory expectations continue to develop.

Weight-loss medicines: a new frontier of risk

Few developments have influenced both the aesthetics sector and the wider healthcare market as profoundly as the emergence of GLP-1 weight-loss medicines.

According to data referenced from the Health Survey for England and NHS prescribing sources, an estimated 1.6 million adults in Great Britain used weight-loss medicines between early 2024 and early 2025.

A further 3.3 million people reportedly expressed an interest in using them. Prescribing volumes increased dramatically, with prescriptions rising from approximately 490,000 in July 2024 to 2.37 million by July 2025. The extraordinary pace of growth has created significant opportunities, but it has also introduced a range of legal, regulatory and insurance considerations.

Many of the legal and liability issues arising from weight-loss medicines mirror those seen more broadly across the aesthetics sector. Patient selection, informed consent, expectation management, monitoring arrangements and record keeping all have the potential to come under scrutiny where outcomes fall short of expectations or adverse events occur.

Particular attention has focused on prescribing pathways. Digital healthcare models have increased accessibility and enabled large numbers of patients to access treatment remotely. While these pathways offer considerable benefits, they also raise questions regarding verification, clinical assessment, medical history review, contraindications, follow-up arrangements and ongoing monitoring responsibilities.

For a more detailed discussion of the legal and claims issues arising from weight-loss medicines, see our recent article on the developing liability landscape surrounding these treatments: Weight-loss medicines: The liability risk beyond the side effects | DWF Group.

Looking ahead

The future of aesthetics is unlikely to be defined by a single treatment, technology or legislative reform.

Instead, it will be shaped by how effectively practitioners, providers, insurers and indemnifiers respond to increasingly complex questions around governance, communication, patient safeguarding and professional accountability.

While innovation will continue to transform the sector, many of the core principles remain unchanged. Effective consent, realistic expectation management, robust record keeping, strong governance and clear professional boundaries remain among the most effective safeguards against complaints, claims and regulatory scrutiny.

As the market continues to expand, the most significant risks may not arise from the procedure itself, but from the systems, decisions and processes that surround it. For clinicians, providers, insurers and indemnifiers alike, the ability to identify and manage those risks proactively is likely to remain a defining feature of good practice.

Many of the themes explored in this article formed part of the discussions at DWF's recent Healthcare Seminar, Beyond Skin Deep: Claims, Compliance and Care in the Aesthetics Arena.